Publications by authors named "Rachel Hodge"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

17

Total Likes

300

Extended Reach

575,532

Social Features

111
C
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Diana Merino Vega, Katherine K Nishimura, Névine Zariffa, Jeffrey C Thompson, Antje Hoering, Vanessa Cilento, Adam Rosenthal, Valsamo Anagnostou, Jonathan Baden, Julia A Beaver

JCO Precis Oncol· August 2022

Videos about Article: user

1 110 4

View All Article and Social Media Activity
T
The synaptic ectokinase VLK triggers the EphB2-NMDAR interaction to drive injury-induced pain.
Kolluru D Srikanth, Hajira Elahi, Praveen Chander, Halley R Washburn, Shayne Hassler, Rachel Hodge

Science· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conceptual framework of women's food environments and determinants of food acquisition and dietary intake in low- and middle-income countries: a scoping review.
Lydia O'Meara, Julia de Bruyn, Tammy Hope, Marta Fajó-Pascual, Rachel Hodge

Lancet Planet Health· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of Germline Stem Cell Competition across Species.
Rachel A Hodge, Erika A Bach

Life (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VLK drives extracellular phosphorylation of EphB2 to govern the EphB2-NMDAR interaction and injury-induced pain.
Kolluru D Srikanth, Hajira Elahi, Praveen Chander, Halley R Washburn, Shayne Hassler, Rachel Hodge

bioRxiv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
Jhanelle E Gray, Ji-Youn Han, Aino Telaranta-Keerie, Xiangning Huang, Alexander Kohlmann, Rachel Hodge

J Mol Diagn· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, Frances A Shepherd, Fumio Imamura, Rachel Hodge

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma.
Owen D Mitchell, Katie Gilliam, Daniela Del Gaudio, Kelsey E McNeely, Shaili Smith, Rachel Hodge

JAMA Netw Open· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The septate junction component bark beetle is required for intestinal barrier function and homeostasis.
Rachel A Hodge, Mirna Ghannam, Emma Edmond, Fernando de la Torre, Cecilia D'Alterio

iScience· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
Yi-Long Wu, Masahiro Tsuboi, Thomas John, Christian Grohe, Margarita Majem, Rachel Hodge

Future Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
Shun Lu, Ignacio Casarini, Terufumi Kato, Manuel Cobo, Mustafa Özgüroğlu, Rachel Hodge

Clin Lung Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohe, Rachel Hodge

N Engl J Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Rachel Hodge

N Engl J Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel self-organizing embryonic stem cell system reveals signaling logic underlying the patterning of human ectoderm.
George Britton, Idse Heemskerk, Rachel Hodge, Amina A Qutub, Aryeh Warmflash

Development· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
Yuichiro Ohe, Fumio Imamura, Naoyuki Nogami, Isamu Okamoto, Takayasu Kurata, Rachel Hodge

Jpn J Clin Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Yi-Long Wu, Myung-Ju Ahn, Marina Chiara Garassino, Ji-Youn Han, Nobuyuki Katakami, Rachel Hodge

J Clin Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho, Manuel Cobo, Eun Kyung Cho, Rachel Hodge

J Clin Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Hiroaki Akamatsu, Nobuyuki Katakami, Isamu Okamoto, Terufumi Kato, Young Hak Kim, Rachel A Hodge

Cancer Sci· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.
Katsuyuki Kiura, Kiyotaka Yoh, Nobuyuki Katakami, Naoyuki Nogami, Kazuo Kasahara, Rachel Hodge

Cancer Sci· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Rachel Hodge

N Engl J Med· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
Suzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, Kenneth S Thress, Karen Yu, Rachel Hodge

J Thorac Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer.
Megan Morisada, Ellen C Moore, Rachel Hodge, Jay Friedman, Harrison A Cash, James W Hodge

Oral Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
Suzanne Jenkins, James C-H Yang, Suresh S Ramalingam, Karen Yu, Sabina Patel, Rachel Hodge

J Thorac Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Corneel Coens, Winette T A van der Graaf, Jean-Yves Blay, Sant P Chawla, Ian Judson, Rachel A Hodge

Cancer· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double deletion of melanocortin 4 receptors and SAPAP3 corrects compulsive behavior and obesity in mice.
Pin Xu, Brad A Grueter, Jeremiah K Britt, Latisha McDaniel, Paula J Huntington, Rachel Hodge

Proc Natl Acad Sci U S A· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis